Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 8/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3006964 | 0.83 | KDM4E (0.38) | SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL20596703 | 0.81 | TACR1 (0.40) | SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL22449324 | 0.78 | SLC6A2 (0.39) | SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL22797936 | 0.78 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL22797956 | 0.78 | TACR1 (0.39) | SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL22797790 | 0.77 | SLC6A2 (0.43) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL22797911 | 0.77 | SLC6A2 (0.44) | SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL22798150 | 0.76 | TACR1 (0.32) | SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL27176078 | 0.76 | TACR1 (0.37) | SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL3008298 | 0.75 | USP30 (0.38) | SLC6A4SLC6A2SLC6A3TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167272-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167272-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | SLC6A4 789/4885SLC6A2 591/4885SLC6A3 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.